生物活性 | |||
---|---|---|---|
描述 | Shikonin is the major bioactive chemical component of Lithospermum erythrorhizon (Purple Cromwell) roots. It shows anticancer activity both in vitro and in vivo. At low concentration, shikonin induced apoptosis in various kinds of cell lines of different origins, including M10 (Mammary epithelial cells), EC109, EC9706 (Esophageal cancer,Esophageal epithelial cells), HCT116, SW620 (Colon cancer), A549 (Lung adenocarcinoma), AGS (Gastric cancer), 8505C8305C, FTC133, BCPAP, TPC1C643IHH4, K (Thyroid cancer) and Htori (Immortalized thyroid epithelial cells), etc.. However, at high concentrations shikonin induced necroptosis in various cancer cell lines. The mode of action of shikonin is associated with cell cycle, glycolysis, metastasis, DNA damage, inflammation, angiogenesis, epigenetics, autophagy or ferroxitosis. In vivo studies showed that shikonin exhibited anti-tumor effects through chemoprevention, cell death or other mechanisms in xenograft, carcinogen-induced, orthotopic or allograft cancer models. Shikonin is also used as a PKM2 inhibitor. Inhibition of PKM2 by shikonin re-sensitized the cisplatin resistant T24 cells and killed the T24 cisplatin resistant cells by inducing necroptosis at concentration of 0.4μM. Recent study found that shikonin showed inhibition effect on 2019-nCoV. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
8-MG-BA cell | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=85.56 nM | SANGER | ||
A101D cell | Growth inhibition assay | Inhibition of human A101D cell growth in a cell viability assay, IC50=0.712 nM | SANGER | ||
A204 cell | Growth inhibition assay | Inhibition of human A204 cell growth in a cell viability assay, IC50=0.12654 μM | SANGER |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01968928 | - | Unknown | December 2016 | Taiwan ... 展开 >> Department of Urology, National Taiwan University Hospital Not yet recruiting Taipei, Taiwan, 10002 Contact: Kuo-How Huang, M.D.,Ph.D. 886-2-23123456 ext 65952 khhuang123@ntu.edu.tw Principal Investigator: Kuo-How Huang, M.D.,Ph.D. 收起 << | |
NCT01287468 | - | Unknown | December 2014 | Taiwan ... 展开 >> Taipei Medical University - WanFang Hospital Taipei, Taiwan 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.47mL 0.69mL 0.35mL |
17.34mL 3.47mL 1.73mL |
34.69mL 6.94mL 3.47mL |
参考文献 |
---|